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Pro-organic radical contrast agents (“pro-ORCAs”)
for real-time MRI of pro-drug activation in
biological systems†
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Nolan Gallagher,a Clelia Mathieu,c,d Michael P. Agius,c,d Oksana Zavidij,c,d
Wencong Wang,a Yivan Jiang,a Andrzej Rajca, g Alan Jasanoff,f,h,i
Irene M. Ghobrial,c,d P. Peter Ghoroghchian*b,c,d and Jeremiah A. Johnson *a,b
Nitroxide-based organic-radical contrast agents (ORCAs) are promising as safe next-generation magnetic
resonance imaging (MRI) tools. Nevertheless, stimuli-responsive ORCAs that enable MRI monitoring of
prodrug activation have not been reported; such systems could open new avenues for prodrug validation
and image-guided drug delivery. Here, we introduce a novel “pro-ORCA” concept that addresses this
challenge. By covalent conjugation of nitroxides and drug molecules (doxorubicin, DOX) to the same
brush-arm star polymer (BASP) through chemically identical cleavable linkers, we demonstrate that pro-
ORCA and prodrug activation, i.e., ORCA and DOX release, leads to significant changes in MRI contrast
that correlate with cytotoxicity. This approach is shown to be general for a range of commonly used linker
cleavage mechanisms (e.g., photolysis and hydrolysis) and release rates. Pro-ORCAs could find appli-
cations as research tools or clinically viable “reporter theranostics” for in vitro and in vivo MRI-correlated
prodrug activation.
Introduction
Theranostic agents—systems that simultaneously provide
therapeutic and diagnostic modalities—are promising tools
for personalized medicine.1–4 These agents can, in principle,
afford molecular insights into disease states and non-inva-
sively report in real-time on the accumulation, release, and
efficacy of therapeutic agents, thereby enabling real-time thera-
peutic selection.3,5,6 Since their multifunctional requirements
are difficult to achieve with small molecules, theranostic
systems are often based on nanoscale materials, which them-
selves possess useful properties such as controllable size and
shape, high loading/multiplexing capability, tunable circula-
tion half-life, predictable biodistribution, and targeted tissue
accumulation.7–9 Indeed, a plethora of theranostic agents
based on nanoscale material scaffolds (e.g., liposomes,
micelles, dendrimers, and polymers) carrying a wide range
of therapeutic entities (e.g., immuno/chemotherapies and
gene therapies) and high sensitivity (fluorescence, PET) or
high-resolution (CT, MRI) imaging modalities have been
reported.10–24
“Smart” or “reporter” theranostics that leverage their
imaging component to elucidate material-disease tissue inter-
actions such as drug release kinetics, efficacy, or acquired
therapeutic resistance are especially powerful.3,25–28 Elegant
work using fluorescence- or FRET-based reporters of cellular
apoptosis or drug release within the tumor microenvironment
have been developed.29–36 Despite the highly innovative nature
of these approaches and their immense utility as research
tools, the translational potential of fluorescence imaging may
be limited by light penetration depth and tissue autofluores-
cence. Alternatively, MRI offers high resolution, safety, and
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established clinical utility.24,25 “Reporter” theranostic
materials that allow for correlation of drug release with MRI
signal changes upon release of Gd-based contrast agents (CAs)
or changes to the delivery vehicle itself have been
reported.37–40 Though metal-based MRI CAs have found wide-
spread clinical utility, they continue to face safety concerns41,42
that have led to discontinuation or withdrawal of several
products.43–47 Metal-free organic radical contrast agents
(ORCAs) have been intensely studied in recent years to over-
come the safety issues of metal-based CAs;48–58 however, to our
knowledge, there are no reports of theranostic ORCAs for MRI-
correlated drug release.
We have extensively investigated bottlebrush and related
brush-arm star polymer (BASP) polymer architectures for appli-
cations in self-assembly, energy storage, drug delivery and
imaging, including as ORCAs for MRI.59–71 BASPs can be
readily covalently conjugated to biocompatible components
such as polyethylene glycol (PEG) as well as single or multiple
prodrug payloads or imaging agents through the use of
branched macromonomers (MMs).59–67,71 PEG-based BASPs
have displayed excellent safety profiles in mice and higher
species, their synthesis is highly scalable and reproducible,
and through MM design, the BASP prodrug activation mecha-
nism and rate can be precisely defined.59–67 BASPs carrying a
high concentration of spirocyclohexyl nitroxides (chex72) cur-
rently represent promising ORCAs for MRI, proving useful for
T2-weighted MRI of tumors in vivo.
64–66,71
A significant challenge in the field of polymer-based pro-
drugs, including BASP prodrugs, lies in the real-time monitor-
ing of prodrug activation, i.e., conversion of polymer-bound
prodrug into free drug, in biological systems. Prodrug acti-
vation kinetics can significantly impact therapeutic outcomes:
activation that occurs too quickly or too slowly can be detri-
mental.62 Most prodrugs do not provide facile spectroscopic
readouts upon activation; thus, liquid chromatography with
tandem mass spectrometry (LC-MS-MS) or inductively coupled
plasma mass spectrometry (ICP-MS) are traditionally used to
quantify prodrug versus free drug in tissue samples of interest.
These methods require tissue harvesting and thus are inher-
ently invasive, ex vivo techniques. The development of non-
invasive, safe, “turn-ON/OFF” MRI probes that enables real-
time correlation of prodrug activation could offer powerful
new research tools and clinical readouts for prodrug
development.
Toward addressing this challenge, we describe herein a
novel “pro-ORCA” design concept wherein the release of co-
valently conjugated ORCAs from a BASP scaffold is shown to
induce a large (∼30-fold) change in magnetic relaxivity that
correlates with prodrug activation. Our proof-of-principle pro-
ORCA system is based on BASPs that feature both nitroxide
ORCAs (for MRI imaging) and the Top2 poison doxorubicin
(DOX) covalently conjugated to the same BASP through chemi-
cally equivalent linkers that cleave in response to either exter-
nal or endogenous triggers (Fig. 1). Linker cleavage events, i.e.,
pro-ORCA and prodrug activation, cause the nitroxide and
DOX to diffuse away from the BASP. The former leads to a ∼30-
fold change in transverse relaxivity and a concomitant change
in MRI contrast, while the latter leads to DOX-induced cell
death, enabling MRI-based, real-time monitoring of prodrug
activation in a simple, modular format. This basic pro-ORCA
concept (Fig. 1) is shown to apply to multiple widely-used trig-
gering mechanisms, variable release kinetics, and in vitro and
in vivo models, offering a promising new concept for MRI-
guided prodrug activation.
Experimental section
Relaxivity and in vitro measurements by MRI
Phantom MRI data were acquired in a 12 cm outer diameter
birdcage transceiver for imaging in a 20 cm bore Bruker 7T
Avance III MRI scanner. For relaxivity determination, samples
at varying concentrations in PBS buffer were used. For in vitro
measurements, samples were prepared as described below,
Fig. 1 Design concept for brush-arm star polymer (BASP) pro-ORCAs. Macromonomers (MMs) featuring a pro-ORCA nitroxide (for MRI) and a
prodrug (therapeutic) conjugated through cleavable linkers are copolymerized with a non-cleavable fluorophore-conjugated MM via the brush-first
ring-opening metathesis polymerization (ROMP) method. The resulting BASP, which carries both the pro-ORCA and prodrug on the same polymer,
displays high transverse relaxivity (r2) enabling T2-weighted MRI. Moreover, the prodrug is therapeutically inactive. Upon cleavage of the linkers that
connect the nitroxide and drug to the BASP, i.e., pro-ORCA and prodrug activation, the nitroxide relaxivity drops significantly leading to a change of
MRI contrast while the drug becomes therapeutically active. Thus, MRI signal changes (in this case, return of negative T2 contrast back to baseline)
can be correlated with prodrug activation. Meanwhile, the fluoroscence signal should not change significantly before and after nitroxide and drug
release, providing a constant imaging handle to visualize the BASP.
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and loaded into a 384-well clear polystyrene plate (Thermo
Scientific Nunc), which had been pre-cut in half to optimally
fit the coil. Unused wells were filled with PBS buffer. 2 mm
slices were imaged through the samples with the field of view
of 5 × 5 cm; and, the data matrices were 256 × 256 points.
Longitudinal (r1) and transverse (r2) relaxivity measure-
ments were acquired using multi-spin multi-echo (MSME)
sequences (flip angle = 180°). r1; TE = 12 ms, TR = 300, 350,
400, 450, 500, 600, 800, 1000, 1200, 1500, 3000, 5000,
10 000 ms. r2; TR = 5000 ms, TE = 12, 24, 36, 48, 60, 72, 84,
96, 108, 120, 132, 144, 156, 168, 280, 192, 204, 216, 228, 240,
252, 264, 276, 288, 300, 312, 324, 336, 348, 360 ms. Custom
routines written in Matlab (Mathworks, Natick, MA) were
used to reconstruct the images and compute relaxation time
constants by fitting image intensity data to exponential decay
curves.
For in vitro measurements, cells (A549, MM.1S, and
KMS11) were plated at 10 000 cells per well in a 96 well plate
and incubated overnight. PC2 (17 mg BASP mL−1, 107 µM
DOX) was then added, and cells were incubated for another
2 h. Excess PC2 was removed via media wash, and fresh
media was added. Cells were then either exposed to UV for
30 min (+UV) or not (−UV). Cells were then incubated for pre-
determined time points (2 h, 6 h, 24 h, or 48 h), then subject
to either MRI or viability assay (CellTiter-Glo, following stan-
dard operating procedure). For cells that were imaged by
MRI, the media was removed. The wells were then filled with
PBS (50 μL), mixed with 1% Triton X-100, transferred to a 384
well plate, and imaged using the MRI protocol described
above.
Cell culture
Human multiple myeloma cells (MM.1S and KMS11, ATCC)
were cultured in RPMI media (Thermo Fisher Scientific) and
were supplemented with 10% fetal bovine serum (FBS, VWR),
1% penicillin/streptomycin (Thermo Fisher Scientific), and 1%
glutamine (Thermo Fisher Scientific). Human lung adeno-
carcinoma cells (A549, ATCC) were cultured in RPMI media,
which was supplemented with 10% FBS and 1% penicillin/
streptomycin. Cell lines were authenticated by short tandem
repeat DNA profiling and were confirmed to be mycoplasma
negative, using the MycoAlert Mycoplasma Testing Kit (Lonza).
All cells were housed in 5% CO2 humidified atmosphere at
37 °C.
In vitro cell viability
MM.1S, KMS11, and A549 cells were plated at 10 000 cells per
well overnight in a 96 well plate. The media was then replaced
with fresh media containing BASPs at various concentrations.
The plate was incubated for 48 h unless otherwise stated; cell
viability was then determined using the CellTiter-Glo assay
(Promega).
For viability assays involving DOX-PC or chex-PC, cells were
plated at 10 000 cells per well in a 96 well plate and incubated
overnight. Cells were incubated for 2 h with DOX-PC or chex-
PC at various concentrations. Excess DOX-PC was removed via
media wash, and fresh media was added. Cells were then
either exposed to UV for 30 min (+UV) or not (−UV). Viability
was evaluated at 48 h with CellTiter-Glo.
Animal usage
All animal studies were conducted under federal, state, and
local guidelines in accordance with the Public Health Service
Policy on Humane Care and Use of Laboratory Animals and
the National Institutes of Health Guide for the Care and Use of
Laboratory Animals with approval from the Massachusetts
Institute of Technology Committee on Animal Care. MR in vivo
tumor imaging was performed at the Brain and Cognitive
Science Complex at MIT. IVIS imaging was performed at the
David H. Koch Institute for Integrative Cancer Research at
MIT. NCR/NU mice (female, 8–12 weeks old, Taconic; n =
3 mice per group) were used for imaging studies.
In vivo therapeutic efficacy of DOX-MHC-BASP
A549 cells were cultured following the protocol described
above to a final concentration of 20%. Cells were then har-
vested, mixed with Matrigel and sterile pH 7.4 PBS buffer
(1 : 1), filtered through sterile 0.2 µm filters, and injected sub-
cutaneously (2.0 × 106 cells) into the hind flank of NCR-NU
mice. Tumor growth was monitored for 2–4 weeks until appro-
priate cumulative diameters (∼1 cm, measured by a digital
caliper) were achieved. Tumor-bearing mice were then random-
ized into groups of n = 3 and injected intratumorally with
50 µL of DOX-M at varying concentrations (1, 2.5, 5, 10 mg
BASP mL−1). Tumor growth was then accessed via caliper
measurements for 25 days.
In vivo MRI instrumentation
In vivo MRI was acquired using a Bruker 9.4T Biospec MRI
scanner using a cross coil volume transmitter and surface
receiver configuration. The tumor region was localized in the
focal spot of the surface coil, with the animal restrained in
order to allow unhindered breathing while minimizing motion
around the hind leg and tumor. Axial T1 weighted images
(T1WIs) were collected using a RARE pulse sequence with TR =
721.1 ms; TE(eff ) = 11.8 ms; RARE factor = 4; FOV = 30 ×
30 mm2; 256 × 256 matrix and 4 averages over 12 slices of
1 mm thickness and 0 mm gap, with a total scan time of
2 min 18 s. Axial T2 weighted images (T2WIs) were collected
using a RARE pulse sequence with TR = 4000 ms; TE(eff ) =
48 ms; RARE factor = 8; FOV = 30 × 30 mm2; 256 × 256 matrix
and 2 averages over 12 slices of 1 mm thickness and 0 mm
gap, with a total scan time of 3 min 12 s. Images were analyzed
using either ImageJ or custom routines written in Matlab
(Mathworks, Natick, MA).
In vivo MRI in tumor-bearing mice
Tumor-bearing NCR-NU mice were generated as described
above. MRI and NIRF images were acquired for each animal (n
= 3 mice per group) before injections. BASPs were prepared,
passed through a sterile 0.2 µm filter, and administered
directly into the tumor via intratumoral injections (50 µL of
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70 mg mL−1 BASPs, F, M, or S). Tumor imaging was done at
pre-determined time points.
In vivo MRI data analysis
T2-weighted images were inverted before analysis was per-
formed so that high T2 regions would appear bright. Signal
intensities pre- and post-injection were compared using only
slices in which tumors and muscle were clearly visible. Using
ImageJ software (v.1.52i), a region of interest (ROI) around
each component was manually drawn. The average signal
intensities and areas of the ROIs were measured; these data
were then normalized against the signal intensity of the
muscle tissue. This process was repeated for all relevant slices
for a given organ; the sum of these signal intensities was then
calculated and divided for the total area, affording the volume-
averaged signal intensity. SNR variations were acquired via nor-
malization against the earliest time point. A detailed step-by-
step analysis is included in the ESI.†
Ex vivo fluorescence imaging
For the 24 h time point, mice were euthanized and their
tumors were harvested (n = 3 mice per group). Tumor slices
were mounted with DAPI staining and imaged with an upright
Carl Zeiss microscope with an HXP 120C light source at 20×
magnification (DAPI λex/λem = 365/445 nm; Cy5.5 λex/λem = 640/
690 nm; DOX λex/λem = 470/525 nm).
Results and discussion
We initially targeted photoresponsive linkers to establish the
pro-ORCA concept for MRI-correlated prodrug activation.
Photocleavable linkers based on ortho-nitrobenzyl (ONB)
derivatives have been widely used in the context of protecting
group chemistry, drug delivery, and materials applica-
tions,73–79 and while such linkers may have translational limit-
ations, they offer powerful research tools for triggering
specific, light-induced biological responses. DOX was chosen
as the therapeutic payloads due to its clinical utility, its estab-
lished mechanisms of action (in both prodrug and free drug
forms), and its inherent fluorescence, the latter of which pro-
vides a useful secondary imaging handle for our proof-of-
concept studies.59–61,67,80 We have previously shown that con-
jugation of DOX to BASPs via an ONB linker deactivates the
drug (i.e., it is a prodrug), providing no detectable release or
cytotoxicity in cell culture over 72 h in the absence of 365 nm
light.59–61,67 Here, we reasoned that this “on/off” nature of
light-induced release would simplify our system by enabling a
binary readout upon irradiation. A previously reported MM
with DOX59 and a new MM with chex conjugated via chemi-
cally identical ONB linkers (Scheme 1A, see ESI† for full syn-
thetic details) were prepared; their structures were confirmed
by electron paramagnetic resonance spectroscopy (EPR;
Fig. S1†), matrix-assisted laser desorption ionization time-of-
flight mass spectroscopy (MALDI-ToF MS; Fig. S2†), and
nuclear magnetic resonance (NMR) spectroscopy (Fig. S3†)
where appropriate. Four BASPs comprising either 100% chex
(chex-PC) or 100% DOX (DOX-PC) or different chex : DOX
ratios (1 : 1 and 27 : 1; PC1 and PC2, respectively, Table 1) were
synthesized via the brush-first ring-opening metathesis
polymerization (ROMP) strategy using an acetal-based bis-nor-
bornene cross-linker (AXL) and Grubbs 3rd-generation bis-pyri-
dine complex (G3) (Scheme 1B).59–62,66 Leveraging the
efficiency of ROMP and the branched MM design,59–66
different chex : DOX ratios can be conveniently realized by
altering the stoichiometry of MM feed ratios. Gel permeation
chromatography (GPC) and dynamic light scattering (DLS) ana-
lyses confirmed high MM-to-brush and brush-to-BASP conver-
sions and consistent sizes and size distributions for these four
particles; the hydrodynamic diameters (Dh) were all ∼22 ±
5 nm (Fig. S4a† and Table 1), highlighting the payload-agnos-
tic nature of BASP synthesis. A cy5.5-based MM (Cy-MM) was
also incorporated into BASPs that were intended to be
deployed for in vivo studies; the cy5.5 dye is non-releasable,
providing an independent imaging handle for the BASP
scaffold that enables validation of the pro-ORCA design
(vide infra). EPR spectroscopy revealed the characteristic broad-
ening associated with conjugation of chex to BASPs
(Fig. S4b†).64–66 Moreover, large per-chex r2 relaxivity enhance-
ments compared to the model nitroxide 3-CP (∼30-fold),
similar to those reported previously upon conjugation of chex
to BASPs,64–66 were observed (Table 1). This result was encoura-
ging, as it confirmed that chex-conjugated BASPs display high
r2 values when cleavable pro-ORCAs linkers are used (previous
work has exclusively used non-releasable chex linkers) and in
the presence of a second payload such as DOX bound to the
same polymer.
To examine light-induced pro-ORCA and pro-drug acti-
vation, DOX-PC, chex-PC, and PC1 (1 : 1 chex : DOX) were
exposed to 365 nm light (see ESI† for details). Samples of the
reactions were taken at various timepoints and were analyzed
by liquid chromatography-MS (LC-MS). The release behaviors
were consistent for the three BASPs (Fig. 2A) with maximal
release occurring with ∼30 min of light exposure regardless of
the payload (i.e., DOX, chex, or 1 : 1 DOX : chex). As such, an
exposure duration of 30 min was used for subsequent
experiments.
To confirm that photoinduced DOX prodrug activation
induces cell death, DOX-PC was incubated with suspended
multiple myeloma (MM.1S and KMS11) and adherent lung
adenocarcinoma (A549) cells for 3 h to provide sufficient time
for uptake. Excess DOX-PC was then removed by media
washing, and the cells were exposed to 365 nm light for
30 min. After incubation for an additional 48 h, cell viability
was assessed using the CellTiter-Glo kit (Fig. 2B). Consistent
with our expectations, significantly greater toxicity was
observed with all cell lines following exposure to 365 nm light
when compared to its absence; note that exposure of cells to
365 nm light in the absence of DOX-PC induced no observable
toxicity (99+% viability in all 3 cell lines). Moreover, irradiation
of cells exposed to chex-PC rather than DOX-PC under the
same conditions led to no meaningful effects at similar con-
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centrations (Fig. S5†). These results confirm the low/no in vitro
toxicities imparted by the pro-ORCA alone, the polymer com-
ponents of the BASP, or from 365 nm light. Only light-triggered
DOX prodrug activation induces significant cell death.
Motivated by these results, we examined the use of PC2 for
correlation of DOX prodrug activation with changes in MRI
contrast in vitro. PC2, which has a chex : DOX ratio of 27 : 1,
was designed to maximize the MRI signal at practical concen-
trations (i.e., high chex loading) and to still provide sufficient
amounts of DOX to induce toxicity following 365 nm light
exposure. Cells were incubated with PC2 (17 mg PC2 mL−1;
107 µM of conjugated DOX) following the same procedure as
described above. The cells were imaged using a 7T MRI
scanner (Fig. 2C). MRI SNR was measured as a function of
time. In support of our design concept, these SNR values corre-
lated with cell viability (Fig. 2D). Upon irradiation, a dimin-
Scheme 1 Photoactivatable BASP pro-ORCA + prodrug design. (A) Chemical structures of MMs chex-PC-MM, DOX-PC-MM, and Cy-MM. The latter
two MMs were reported previously, while chex-PC-MM was newly synthesized to enable photocontrolled release of chex. Grubbs 3rd generation
bis-pyridine complex (G3, py = pyridine) and acetal-based crosslinker AXL structures are also shown. (B) Brush-first ROMP was conducted by expos-
ing mixtures of the MMs listed above to G3 to generate short bottlebrush polymers. Subsequent addition of AXL induces cross-linking to provide
photocleavable BASP “reporter” theranostic agents (e.g., PC1 and PC2). Exposure to light (365 nm) releases chex and DOX from the BASP, inducing
concomitant changes in MRI signal and therapeutic efficacy.
Polymer Chemistry Paper
This journal is © The Royal Society of Chemistry 2020 Polym. Chem.
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
6 
Ju
ne
 2
02
0.
 D
ow
nl
oa
de
d 
on
 7
/2
7/
20
20
 1
0:
03
:5
4 
A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
ished T2 MRI signal was observed as the molar transverse
relaxivity of the nitroxide decreases by ∼30-fold upon release
(Table 1, r2 of water-soluble chex analogue 3-CP = 0.17 mM
−1
s−1 compared to PC2, which has a per-chex r2 of 4.91 mM
−1
s−1). Substantial SNR changes were observed in all three irra-
diated cell lines (Fig. 2D, black solid curves) when compared
to non-irradiated cells (Fig. 2D, black dotted curves). For
instance, in the case of MM.1S a 57 ± 3% decrease in the T2
signal was observed from irradiated cells as compared to 5 ±
2% for non-irradiated cells. Finally, the MRI SNR data corre-
lated with cytotoxicity (Fig. 2D, red solid curves) at all time
points up to 48 h, indicating that chex and DOX are cleaved
and diffuse away from the BASP at similar rates and that the
latter was therapeutically active. Altogether, these results
demonstrate proof-of-principle for the pro-ORCA concept,
showing that light-induced prodrug activation correlates with
MRI signal in vitro (Fig. 2D).
Having established proof-of-concept for our pro-ORCA
design, we sought to further demonstrate its generally using
more translationally-relevant ester-based prodrugs.81 Three
Table 1 Characterization data for all BASPs synthesized in this study as well as the model nitroxide 3-CP for comparison
Sample name Linker chex:G3 DOX:G3 cy:G3 Dh/nm r1/mM
−1 s−1 r2/mM
−1 s−1
DOX-PC PC 0 7 0 22 ± 5 — —
chex-PC PC 7 0 0 21 ± 4 0.31 5.05
PC1 PC 3.5 3.5 0 22 ± 4 0.25 5.43
PC2 PC 6.75 0.25 0 22 ± 6 0.29 4.91
DOX-S HC, S 0 7 0 21 ± 3 — —
chex-S HC, S 7 0 0 20 ± 4 0.27 5.02
S HC, S 6 1 0.07 21 ± 5 0.29 5.01
DOX-M HC, M 0 7 0 21 ± 4 — —
chex-M HC, M 7 0 0 20 ± 5 0.22 4.37
M HC, M 6 1 0.07 20 ± 5 0.21 4.69
DOX-F HC, F 0 7 0 20 ± 3 — —
chex-F HC, F 7 0 0 18 ± 5 0.32 4.94
F HC, F 6 1 0.07 21 ± 5 0.26 4.85
C N/A N/A N/A N/A 20 ± 4 — —
3-CP51 N/A N/A N/A N/A N/A 0.15 0.17
PC = photocleavable; HC = hydrolytically cleavable (ester-based linker); G3 = Grubbs 3rd generation bis-pyridine complex; Dh = hydrodynamic dia-
meter as measured by dynamic light scattering; per-nitroxide r1 and r2 values; S, M, and F refer to the ester linker used to form the corresponding
BASP: slow-, medium-, and fast-releasing.
Fig. 2 In vitro investigations of photocleavable (PC)-BASP pro-ORCAs and prodrugs. (A) Chex and DOX release from PC-BASPs as a function of
irradiation (365 nm) time as determined by liquid chromatography-mass spectrometry (LC-MS). (B) In vitro toxicity of DOX-PC with (red curves) or
without (black curves) light-triggered release as examined upon addition to different cancer cell lines (multiple myeloma – MM.1S and KMS11; lung
adenocarcinoma – A549). Data are presented as mean ± SEM (n = 3). (C) T2-Weighted MRI of cancer cells 2, 6, 24, and 48 h after addition of PC2.
False-color inverse-contrast was applied for visualization. (D) MRI signal quantification, revealing changes in SNR that track with incubation time
post-UV. Data are presented as mean ± SEM (n = 3); statistical analyses between pre- and post-light exposure (±hυ) for T2 MRI SNR variation (black)
and cell viability (red) were performed using 2-tailed student t-test (n.s.: not significant, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001).
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ester linkers were designed and used to prepare pro-ORCAs
and DOX prodrugs (Scheme 2A): one that was previously
reported to display excellent in vivo efficacy when conjugated
to DOX60,61 (referred to herein as “medium”) and two novel
linkers with steric and electronic properties tuned to afford
relatively “fast” and “slow” hydrolysis kinetics in vitro. These
linkers utilize the same release mechanism: hydrolytic clea-
vage of the aromatic ester (rate-determining step), followed by
a 1,6-elimination73 to release free DOX. Control over their
hydrolysis rate is predictable and tunable using rational struc-
tural modifications. Using these 3 linkers, 6 different MMs
were synthesized: DOX-S-MM; DOX-M-MM;60 DOX-F-MM;
chex-S-MM; chex-M-MM; and chex-F-MM where S, M, and F
correspond to the linker structure: slow, medium and fast,
respectively (Scheme 2A, see ESI† for synthetic details). To vali-
date the structures of these MMs (Fig. S6–18†), EPR spec-
troscopy (Fig. S6, S9, and S12†), NMR spectroscopy (Fig. S7,
S10, S13, S15 and S17†), and MALDI-ToF MS (Fig. S8, S11, S14,
S16, and S18†) were deployed where appropriate.
To confirm their relative release rates, the MMs were incu-
bated in PBS (pH 7.4) buffer; the amounts of released DOX or
chex were quantified as a function of time via LC-MS. The
Scheme 2 Hydrolytically labile ester-based BASP pro-ORCAs and prodrugs. (A) Chemical structures of 6 synthesized MMs featuring chex or DOX
conjugated via slow, medium, or fast releasing linkers. (B) Brush-first ROMP was used to synthesize BASP “reporter” theranostic agents. Here, release
of chex and DOX via ester hydrolysis leads to concomitant MRI and efficacy changes that correlate with the measured hydrolysis rates.
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pseudo-first order rate constants for release of DOX from
DOX-F-MM, DOX-M-MM, and DOX-S-MM were 21.26 × 10−3
h−1, 8.95 × 10−3 h−1, and 3.62 × 10−3 h−1, respectively (Fig. 3A
and Table S1†) while the pseudo-first order rate constants for
release of chex from chex-F-MM, chex-M-MM, and chex-S-MM
were 8.23 × 10−3 h−1, 4.31 × 10−3 h−1, and 1.63 × 10−3 h−1,
respectively (Fig. S15 and Table S1†). Although these rate con-
stants are not identical across DOX and chex pairs due to
differences in the physical properties (e.g., hydrophobicity) of
chex and DOX, the DOX : chex release rate ratios were similar:
2.58, 2.08, and 2.22 for the F, M, and S pairs, respectively,
which enables correlation of DOX prodrug and pro-ORCA acti-
vation (vide infra). We note that these in vitro release kinetics
studies were conducted using MMs rather than BASPs to ease
sample handling and analysis. Though release from BASPs is
generally much slower than from MMs using the same linker,
trends in release kinetics across different linkers are pre-
served.62 Next, these 6 MMs were used to prepare 6 different
singly-loaded BASPs (DOX-F, DOX-M, DOX-S, chex-F, chex-M,
chex-S) (Scheme 2B). GPC and DLS results confirmed that the
BASP sizes (∼21 nm) were independent of the payload (DOX or
chex) or linker (F, M, or S); EPR spectroscopy and MRI-
measured per-chex r2 values for the three BASP pro-ORCAs
showed that the magnetic properties of chex were not mean-
ingfully affected by the linkers (Fig. S20–22† and Table 1).
Cell viability assays were conducted with the same 3 cell
lines used above following 48 h incubation with these 6 BASPs.
As expected, negligible toxicity was observed for the pro-
ORCAs lacking DOX (Fig. S23†). In contrast, the toxicity of the
DOX prodrug BASPs increased with the rate of DOX release
(Fig. 3B); in MM.1S cells, DOX-F, DOX-M, and DOX-S exhibited
IC50 values of 3.1 µM, 17.4 µM, and 113.3 µM DOX, respect-
ively. Given that these BASPs have similar sizes and compo-
sitions (Table 1) and, thus, expectedly similar cellular internal-
ization rates, this toxicity trend is likely due to varying levels of
DOX prodrug activation and release within the 48 h incubation
period. Moreover, the DOX-F viability curve approaches that of
free DOX (IC50 of 2.9 µM for MM.1S), suggesting that the
majority of DOX may be released from this material in this
timeframe (Fig. S24†). Next, viability assessments of MM.1S
and A549 were performed as a function of exposure time to
each DOX-containing BASP using a fixed dose of 0.5 mg mL−1
BASP (83–86 µM DOX; Fig. S25†). Validating our prodrug
linker design, the toxicity toward both cell lines followed the
same trend: DOX-F > DOX-M > DOX-S.
In order to inform subsequent studies of MRI-guided moni-
toring of prodrug activation, we studied the in vivo toxicity of
DOX-M using a subcutaneous lung adenocarcinoma (A549)
model. A549 cells were injected into the hind flank of BALB/c
mice (4 groups of n = 3 mice). Once the tumors reached ∼1 cm
in diameter, the mice were randomized and each received a
single 50 µL intratumoral dose (day 0) of 0 (blank), 1, 5, or
10 mg mL−1 of DOX-M. Intratumoral administration was
selected to maximize tumor MRI SNR and preclude variables
of tumor accumulation and pharmacokinetics, thereby simpli-
fying imaging studies for this proof-of-concept work
(vide infra). It should be noted that intratumoral drug delivery
is a clinically-viable strategy for cancer therapy;82–85 ∼200
ongoing clinical trials leverage this method of administration.
Moreover, intratumoral administration of BASPs has not been
demonstrated before. In our study, significant tumor growth
inhibition was observed over the 25 d period of observation
following the administration of DOX-M when compared to the
control group (Fig. S26†). Moreover, a dose-dependent
response was observed; the 10 mg mL−1 (1.7 mM) DOX-M dose
provided gradual tumor shrinkage that we reasoned could
allow for facile comparisons between different ester linkers in
a “reporter” theranostic study.
Based on the above results, a new set of 3 pro-ORCA +
prodrug BASPs – F, M, and S – that each contained both DOX
and chex attached to the same polymer (DOX : chex ratio of 1 : 6
to maximize MRI sensitivity) conjugated via the respective fast-
, medium-, and slow-release ester linkers, as well as 1 mol% of
non-releasable cy5.5, were synthesized and characterized by
GPC, DLS, EPR, and in vitro MRI (Table 1, Fig. S20–22†). The
same subcutaneous A549 murine model was employed to cor-
relate DOX prodrug activation from F, M, and S with MRI SNR
changes in vivo. Each mouse was intratumorally administered
either a pro-ORCA-based BASP (F, M, or S) or a non-cleavable
chex-containing BASP66 as a control (C); note that every animal
Fig. 3 In vitro investigations of hydrolytically labile MMs and BASPs based on ester linkers. (A) DOX release kinetics from DOX-S-MM (blue),
DOX-M-MM (red), and DOX-F-MM (black) in neutral PBS buffer as a function of incubation time as determined by LC-MS. Note: release assays were
conducted for MMs rather than BASPs for ease of analysis. Though release is generally much slower from BASPs compared to MMs using the same
linker, trends in release rates as a function of linker are preserved. (B) In vitro toxicity of DOX-S (blue), DOX-M (red), and DOX-F (black) in different
cell lines. Data are presented as mean ± SEM (n = 3).
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received 50 µL of a 70 mg mL−1 solution, which corresponded
to ∼1.7 mM of conjugated DOX, matching the dose used for
DOX-M (vide supra). T2-Weighted MR images of the tumors
were taken at pre-determined time points, beginning at 30 min
after BASP injection (Fig. 4A). Inversion of image intensity was
performed for subsequent analysis in order to aid visualiza-
tion. In the inverted T2-weighted images, signal decreases
upon pro-ORCA activation; the image appears brightest in the
areas where the pro-ORCA (F, M, or S) concentration is the
highest. Importantly, SNR variations that correlated with the
release kinetics of chex from the corresponding MMs were
observed while no changes were observed for C (Fig. 4B),
which confirmed the ability of this approach to monitor pro-
ORCA activation kinetics in vivo using MRI. For instance, 24 h
post-injection decreases in inverse T2-weighted signal of 80 ±
7%, 49 ± 14%, and 9 ± 1% were observed for F, M, and S,
respectively; the constant signal observed for non-cleavable
BASP C suggests that these BASPs remain in the tumor
environment and that there is an insignificant amount of
BASP-nitroxide degradation (e.g., via reduction) throughout the
timeframe of this study (Fig. 4B and Fig. S27†).66 To support
our findings that these MRI SNR changes correlated with DOX
release, the tumors of mice that had been administered F, M,
and S were extracted for ex vivo fluorescence imaging to corre-
Fig. 4 In vivo examination of hydrolytically labile BASP “reporter” theranostic agents for monitoring drug release in real time. (A) In vivo T2-weighted
MR images at various time points after intratumoral injection of F, M, or S into mice bearing subcutaneous A549 tumors (n = 3 mice per group).
False-color inverted T2-weighted images of the tumor region are overlaid for visualization. These inverted images were used for subsequent analysis.
(B) Quantifcation of the changes in contrast over time in mice administered F, M, S, or non-cleavable control BASP (C)52 (n = 3 mice per group).
Volume-averaged signal intensity across the whole tumor was calculated (see ESI† for full description). Data are presented as the mean ± SEM; stat-
istical analyses were performed using one-way ANOVA (n.s.: not significant, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001). (C) Representative fluorescence
micrographs of tumors from mice administered F, M, or S 24 h post-injection (scale bar: 2 mm). Blue channel: DAPI; red channel: BASP (Cy); green
channel: DOX.
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late the intratumoral locations of DOX (via its inherent fluo-
rescence) with those of the BASPs (via cy5.5 fluorescence)
(Fig. 4C). We stress that fluorescence is used here as a support-
ing tool to validate our MRI measurements for this proof-of-
concept study; most drugs are not inherently fluorescent,
motivating our development of pro-ORCAs. Gratifyingly, the
DOX (green) and BASP (red) signals from the micrographs of
tumors treated with the slow-releasing BASP (S) displayed good
signal co-localization, suggesting that DOX was still conjugated
to the BASP in its prodrug form and in agreement with MRI
SNR variations. In contrast, significant separations of DOX
(green) and BASP (red) were observed for the fast (F) as well as
the medium (M) BASPs, suggesting that DOX release had
occurred at sufficiently earlier time points with these con-
structs. It is, however, difficult to directly compare F and M, as
the fluorescence of DOX is susceptible to alteration by several
biological processes.86,87 Nonetheless, these results support
the fact that T2 MRI signal changes induced by pro-ORCA acti-
vation correlate with DOX prodrug activation in this system,
establishing an example of controlled nitroxide release for cor-
relation of drug release in vivo.
Conclusions
Herein, we introduced design principles and provided in vitro
and in vivo proofs-of-concept for stimuli-responsive pro-ORCAs
that enable real-time, non-invasive monitoring of prodrug acti-
vation in biological systems using a clinically viable imaging
technique (MRI). Specifically, chex ORCAs were conjugated to
BASPs through cleavable linkers generating “pro-ORCAs”.
When attached to the BASP, chex has a large r2 value that,
when combined with the high density of chex on each BASP,
leads to MRI contrast on par with clinically used metal-based
contrast agents; cleavage of the linker that connects chex to
the BASP leads to a ∼30-fold decrease in r2 and concomitant
loss of MRI contrast. By combining this pro-ORCA concept
with DOX prodrugs conjugated to the same BASP using the
same linkers, simultaneous pro-ORCA and prodrug activation
occurs, which leads to changes in MRI contrast that correlate
with drug release. This concept was demonstrated using 4
different linkers: 1 photocleavable and 3 hydrolytically cleava-
ble linkers with different rates of hydrolysis, in both in vitro
and in vivo settings. Regarding the latter, real-time monitoring
of drug release via changes in T2 MRI signals within a tumor
was demonstrated. Altogether, this work establishes a promis-
ing platform technology for monitoring prodrug activation
in vitro and in vivo. We note that while the subject of this study
was the real-time visualization of prodrug activation in biologi-
cal environments via MRI, the demonstrated linker “plug-and-
play” concept can potentially be expanded in the future to
reporters of cell apoptosis or immunogenic cell death.
Moreover, this approach could potentially be expanded to
other therapeutic entities and a range of imaging modalities,
providing valuable research tools as well as clinically translata-
ble systems for personalized medicine.
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